Efficacy and safety of Nd:YAG laser alone compared with combined Nd:YAG laser with intralesional steroid or botulinum toxin A in the treatment of hypertrophic scars

This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p < 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO.

Download Full-text

The Efficacy and Safety of Early Postoperative Botulinum Toxin A Injection for Facial Scars

Aesthetic Plastic Surgery ◽

10.1007/s00266-017-1008-7 ◽

2017 ◽

Vol 42 (2) ◽

pp. 530-537 ◽

Cited By ~ 18

Author(s):

Seo H. Lee ◽

Hyung J. Min ◽

Yang W. Kim ◽

Young W. Cheon

Keyword(s):

Botulinum Toxin ◽

Botulinum Toxin A ◽

Efficacy And Safety ◽

Toxin A

Download Full-text

Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele

Dataset Papers in Medicine ◽

10.1155/2013/580927 ◽

2013 ◽

Vol 2013 ◽

pp. 1-5

Author(s):

Antonio Marte ◽

Micaela Borrelli ◽

Maurizio Prezioso ◽

Lucia Pintozzi ◽

Pio Parmeggiani

Keyword(s):

Botulinum Toxin ◽

Neurogenic Bladder ◽

Botulinum Toxin A ◽

Invasive Procedure ◽

Bladder Capacity ◽

Rank Test ◽

Clean Intermittent Catheterization ◽

Efficacy And Safety ◽

Average Increase ◽

Toxin A

We verified the efficacy and safety of botulinum toxin A (BTX-A) in treating bladder overactivity in children with neurogenic bladder (NB) secondary to myelomeningocele (MMC). Forty-seven patients (22, females; 25, males; age range, 5–17 years; mean age, 10.7 years) with poorly compliant/overactive neurogenic bladder on clean intermittent catheterization (CIC) and resistance or noncompliant to anticholinergics were injected with 200 IU of BTX-A intradetrusor. All patients experienced a significant 66.45% average increase of leak point volume (Wilcoxon paired rank test = 7.169 e-10) and a significant 118.57% average increase of specific bladder capacity at 20 cm H2O (Wilcoxon paired rank test = 2.466 e-12). Ten patients who presented with concomitant uni/bilateral grade II–IV vesicoureteral reflux were treated at the same time with Deflux. No patient presented with major perioperative or postoperative problems. Twenty-two patients needed a second and 18 a third injection of BTX-A after 6–9 months for the reappearance of symptoms. After a mean follow-up of 5.7 years, 38 out of 47 patients achieved dryness between CICs, and 9 patients improved their incontinence but still need pads. Our conclusion is that BTX-A represents a viable alternative to more invasive procedure in treatment of overactive NB secondary to MMC.

Download Full-text